Retatrutide TRIUMPH-4: 28.7% Weight Loss in Phase 3

Lilly's triple hormone agonist delivered the strongest weight-loss results ever in a Phase 3 obesity trial. What TRIUMPH-4 showed and what's coming in 2026.

In December 2025, Eli Lilly announced topline results from TRIUMPH-4 — the first successful Phase 3 trial for retatrutide, an investigational triple hormone receptor agonist. Participants on the 12 mg dose lost an average of 28.7% of their body weight over 68 weeks. That's approximately 71 pounds from a baseline weight of 248.5 pounds.

These are the strongest weight-loss results in the history of obesity pharmacotherapy. They surpass tirzepatide's 20% in SURMOUNT-1 and semaglutide's 15% in STEP-1. They're the reason retatrutide is being watched closely across the entire obesity medicine field — and why FDA approval, while not yet filed, is expected by late 2027 or 2028.

Here's what we know so far.

What Is Retatrutide?

Retatrutide is a once-weekly injectable triple hormone receptor agonist. It's a single molecule that activates three receptors simultaneously:

• GLP-1 — the mechanism shared with semaglutide (Wegovy/Ozempic)
• GIP — the second mechanism added by tirzepatide (Zepbound/Mounjaro)
• Glucagon — the third receptor, which appears to drive additional benefit by increasing energy expenditure and hepatic fat oxidation

The glucagon component is the novel element. Activating the glucagon receptor increases basal metabolic rate and promotes fat burning in the liver — mechanisms that dual agonists don't touch. Theoretically, this is why retatrutide outperforms tirzepatide by roughly 8 percentage points of weight loss in its trials.

The TRIUMPH-4 Results

TRIUMPH-4 was a Phase 3, 68-week, randomized, double-blind, placebo-controlled trial in adults with obesity or overweight plus knee osteoarthritis (a dual-endpoint design — weight loss and pain reduction). 445 participants were randomized 1:1:1 to retatrutide 9 mg, 12 mg, or placebo.

For co-primary endpoints: retatrutide reduced knee osteoarthritis pain by up to 75.8% from baseline and reduced weight by up to 28.7%. Cardiovascular risk markers — non-HDL cholesterol, high-sensitivity CRP, triglycerides, systolic blood pressure (~14 mmHg drop) — all improved significantly.

The Safety Signals

Adverse events were consistent with the incretin class, with some notable numbers:

• Nausea: 43%
• Vomiting: 21%
• Diarrhea: 33%
• Discontinuation due to AEs: 12.2% (9 mg) and 18.2% (12 mg) vs. 4% placebo

Discontinuations were notably higher than with tirzepatide or semaglutide. Lilly attributed some of this to "perceived excessive weight loss" — meaning participants with lower baseline BMI reached target weight faster than anticipated and chose to stop. Future trials include a 4 mg maintenance dose, likely to address this concern.

What's Coming in 2026

TRIUMPH-4 was the first of eight Phase 3 readouts. Seven more are expected throughout 2026 across the TRIUMPH program:

• TRIUMPH-1: Obesity and overweight (the primary registration trial, 80-week duration — analysts predict possibly over 30% weight loss given the longer timeline)
• TRIUMPH-2: Weight management confirmatory trial in an independent population
• TRIUMPH-3: Obesity with established cardiovascular disease
• TRIUMPH-5: Type 2 diabetes and obesity (dual endpoints for A1C + weight)
• OSA, cardiovascular outcomes, and MASH trials: Additional indications under study

Together, the TRIUMPH program has enrolled over 5,800 participants — one of the largest Phase 3 programs ever for an obesity medication.

Regulatory Pathway and Timing

Retatrutide has not yet been filed with the FDA. Lilly is expected to submit after the core TRIUMPH-1 and TRIUMPH-2 readouts in 2026. Based on standard FDA review timelines — and even accounting for potential expedited review programs — the earliest plausible U.S. approval is late 2027 or 2028.

One regulatory subplot worth watching: Lilly is appealing the FDA's classification of retatrutide. The company is challenging whether it should be classified as a drug or a biologic — a distinction with major implications for compounding pharmacy access and generic pathways down the road.

How It Compares to Current Options

If TRIUMPH-1 delivers on analyst expectations of 30%+ weight loss at 80 weeks, retatrutide will define a new efficacy tier entirely — roughly in the range of what bariatric surgery achieves, without the surgery.

Practical Reality for Patients

Retatrutide is not currently available through any legitimate channel. It is an investigational drug. Claims from peptide vendors, research-chemical sellers, or "research-grade" suppliers should be treated with extreme skepticism — these products are not FDA-regulated, have no guaranteed purity or potency, and are not safe for human use regardless of how they're marketed.

Questions Worth Preparing For

When retatrutide eventually receives FDA approval, expect these questions in your provider conversations:

• Is my BMI high enough — and my target weight change significant enough — to justify retatrutide over existing options?
• What's the plan if I lose weight faster than expected (the "excessive weight loss" signal)?
• How will we manage the higher GI side effect rate during titration?
• What does the dysesthesia monitoring look like?
• Will insurance cover retatrutide, or is this a cash-pay reality for the first few years?